Loading...
Enzolytics Inc.
ENZC•PNK
HealthcareBiotechnology
$0.001
$0.00(14.29%)
Enzolytics Inc. (ENZC) Stock Overview
Explore Enzolytics Inc.’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for ENZCStats details for ENZC are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ENZCAnalyst Recommendations details for ENZC are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Enzolytics, Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, it has created a proprietary cell line that produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas.
CEO
Steven Sharabura
Employees
1
Headquarters
2000 North Central Expressway, Plano, TX
Founded
2009